Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework

While anti-PD-1 and anti-PD-L1 [anti-PD-(L)1] monotherapies are effective treatments for many types of cancer, high variability in patient responses is observed in clinical trials. Understanding the sources of response variability can help prospectively identify potential responsive patient populati...

Descripción completa

Detalles Bibliográficos
Autores principales: Leete, Jessica C., Zager, Michael G., Musante, Cynthia J., Shtylla, Blerta, Qiao, Wenlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760747/
https://www.ncbi.nlm.nih.gov/pubmed/36545310
http://dx.doi.org/10.3389/fphar.2022.1056365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760747/
https://www.ncbi.nlm.nih.gov/pubmed/36545310
http://dx.doi.org/10.3389/fphar.2022.1056365

Ejemplares similares